Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease

Blood

Volumn 107, Issue 6, 2006, Pages 2279-2285

  Kato, Gregory J ^a   McGowan, Vicki ^b   Machado, Roberto F ^b   Little, Jane A ^b   Taylor VI, James ^b   Morris, Claudia R ^b   Nichols, James S ^b   Wang, Xunde ^b   Poljakovic, Mirjana ^b   Morris Jr , Sidney M ^b   Gladwin, Mark T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME; LACTATE DEHYDROGENASE ISOENZYME 1; LACTATE DEHYDROGENASE ISOENZYME 2; NITRIC OXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL FREE SYSTEM; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG ULCER; MAJOR CLINICAL STUDY; MALE; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETICULOCYTE; SAMPLE SIZE; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; STEADY STATE; VASCULAR DISEASE;

EID: 33644775612     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2373     Document Type: Article

References (69)

1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
2. Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol. 2005;130:943-953.
3. Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001;20:47-72.
4. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81:96-98.
5. Duits AJ, Rojer RA, van Endt T, et al. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Ann Hematol. 2003;82:171-174.
6. Saleh AW, Duits AJ, Gerbers A, de Vries C, Hillen HF. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1998;100:26-31.
7. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999;102:31-37.
8. Schnog JB, Rojer RA, Mac Gillavry MR, et al. Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol. 2003;82:109-113.
9. Shiu YT, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood. 2000;95:3232-3241.
10. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001;97:1937-1941.
11. Tabbara IA. Hemolytic anemias. Diagnosis and management. Med Clin North Am. 1992;76:649-668.
12. Bensinger TA, Gillette PN. Hemolysis in sickle cell disease. Arch Intern Med. 1974;133:624-631.
13. Naumann HN, Diggs LW, Barreras L, Williams BJ. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol. 1971;56:137-147.
14. Neely CL, Wajima T, Kraus AP, Diggs LW, Barreras L. Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease. Am J Clin Pathol. 1969;52:167-169.
15. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46:105-110.
16. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
17. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271-278.
18. Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Crit Care Respir Med. 2003;168:63-69.
19. Schnog JJ, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-375.
20. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294:81-90.
21. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001;98:15215-15220.
22. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 2005;19:989-991.
23. Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease - mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004;50:95-105.
24. Aslan M, Ryan TM, Townes TM, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem. 2003;278:4194-4204.
25. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000;278:H1799-H1806.
26. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97:1584-1589.
27. Eberhardt RT, McMahon L, Duffy SJ, et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol. 2003;74:104-111.
28. Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1949-R1955.
29. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 2004;114:1136-1145.
30. Minneci PC, Deans KJ, Zhi H, et al. A novel mechanism of disease: hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115:3409-3417.
31. Kopperschlager G, Kirchberger J. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J Chromatogr B Biomed Appl. 1996;684:25-49.
32. Adhikary PK, Hara S, Dwivedi C, et al. Vasoocclusive crisis episodes in sickle cell disease. J Med. 1986;17:227-240.
33. Sonntag O. Haemolysis as an interference factor in clinical chemistry. J Clin Chem Clin Biochem. 1986;24:127-139.
34. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
35. Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci U S A. 2005;102:2531-2536.
36. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. 2004;76:245-251.
37. Rybicki AC, Fabry ME, Does MD, Kaul DK, Nagel RL. Differential gene expression in the kidney of sickle cell transgenic mice: upregulated genes. Blood Cells Mol Dis. 2003;31:370-380.
38. Lee SK, Kim JH, Yang WS, et al. Exogenous nitric oxide inhibits VCAM-1 expression in human peritoneal mesothelial cells. Role of cyclic GMP and NF-kappaB. Nephron. 2002;90:447-454.
39. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996;93:9114-9119.
40. Cartwright JE, Whitley GS, Johnstone AP. Endothelial cell adhesion molecule expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide. Exp Cell Res. 1997;235:431-434.
41. Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol. 2000;63:200-204.
42. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
43. Gurkan E, Tanriverdi K, Baslamisli F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol. 2005;84:71-75.
44. Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 2003;362:1450-1455.
45. Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am J Hematol. 1991;36:122-130.
46. Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol. 2004;126:606-611.
47. Dore F, Bonfigli S, Pardini S, Pirozzi F, Longinotti M. Priapism in thalassemia intermedia [letter]. Haematologica. 1991;76:523.
48. Stevens DM, Shupack JL, Javid J, Silber R. Ulcers of the leg in thalassemia. Arch Dermatol. 1977;113:1558-1560.
49. Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69:320-325.
50. Macchia P, Massei F, Nardi M, et al. Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica. 1990;75:486-487.
51. Rao KR, Patel AR. Priapism and thalassaemia intermedia [letter]. Br J Surg. 1986;73:1048.
52. Jackson N, Franklin IM, Hughes MA. Recurrent priapism following splenectomy for thalassaemia intermedia. Br J Surg. 1986;73:678.
53. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145.
54. Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major [letter]. Am Heart J. 1999;138:384.
55. Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 1991;4:629-631.
56. Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57:82-84.
57. Jardine DL, Laing AD. Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. Intern Med J. 2004;34:214-216.
58. Giraldi S, Abbage KT, Marinoni LP, et al. Leg ulcer in hereditary spherocytosis. Pediatr Dermatol. 2003;20:427-428.
59. Lawrence P, Aronson I, Saxe N, Jacobs P. Leg ulcers in hereditary spherocytosis. Clin Exp Dermatol. 1991;16:28-30.
60. Goulding FJ. Priapism caused by glucose phosphate isomerase deficiency. J Urol. 1976;116:819-820.
61. Thuret I, Bardakdjian J, Badens C, et al. Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu→Arg. Am J Hematol. 1996;51:133-136.
62. Edney MT, Schned AR, Cendron M, Chaffee S, Ellsworth PI. Priapism in a 15-year-old boy with congenital dyserythropoietic anemia type II (hereditary erythroblastic multinuclearity with positive acidified serum lysis test). J Urol. 2002;167:309-310.
63. Christakis J, Vavatsi N, Hassapopoulou H, et al. Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet. 1990;335:637-640.
64. Kar BC, Satapathy RK, Kulozik AE, et al. Sickle cell disease in Orissa State, India. Lancet. 1986;2:1198-1201.
65. Dash BP, Kar BC. Priapism is rare in sickle cell disease in India. J Assoc Physicians India. 2000;48:255.
66. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis associated priapism in sickle cell disease. Blood. 2005;106:3264-3267.
67. Homi J, Levee L, Higgs D, Thomas P, Serjeant G. Pulse oximetry in a cohort study of sickle cell disease. Clin Lab Haematol. 1997;19:17-22.
68. Rackoff WR, Kunkel N, Silber JH, Asakura T, Ohene-Frempong K. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood. 1993;81:3422-3427.
69. Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol. 2005;131:129-134.